Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Renal Cell Carcinoma | Access and Reimbursement | US | 2018

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Two of the largest U.S. pharmacy benefit managers, Express Scripts and CVS Health, set in motion a new approach to drug reimbursement by introducing indication-specific pricing (ISP). Instead of reimbursing a drug the same way across all indications for which it is approved, the PBMs have set up programs to vary reimbursement and formulary placement of some drugs based on their clinical value in different indications or patient subpopulations. This study examines the potential for this strategy to take hold with U.S. managed care organizations’ coverage of oncology drugs. Payers are surveyed about the potential for using an ISP strategy with drugs to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), while oncologists are queried on their receptivity to this game-changing strategy.

QUESTIONS ANSWERED

  • What is the current access and prescribing landscape for RCC and HCC as new label expansions create more treatment alternatives?
  • What is the future for ISP in oncology and are MCOs employing this strategy now?
  • What are or will be the major challenges to varying pricing and/or coverage by indication and how do/will MCOs track diagnosis to implement ISP?
  • Do oncologists ever encounter situations where the drugs they prescribe are covered differently by indication, and what is their reaction to this trend?

PRODUCT DESCRIPTION Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
north_east
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
north_east
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east